PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$5.56 -0.1  -2.3%

Last Trade - 7:45pm

Sector
Healthcare
Size
Small Cap
Market Cap £120.0m
Enterprise Value £68.3m
Revenue £n/a
Position in Universe 4970th / 7414

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

Mon 6th December, 2021 1:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211206:nGNX7SL0vf&default-theme=true


FLORHAM PARK, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies based on the Company’s proprietary Versamune® T-cell
activating technology, today announced the reopening of recruitment in the
National Cancer Institute (NCI)-led Phase 2 clinical trial (NCT04287868)
evaluating PDS0101 (Versamune®-HPV16) in combination with two investigational
immune-modulating agents in advanced HPV cancers.

The suspension of recruitment was administrative in nature and was unrelated
to any specific safety or efficacy concerns associated with the triple
combination being studied. As a result, during the recruitment suspension,
patients already enrolled in the study continued to receive scheduled
treatment. The timing of clinical results from this trial is not expected to
be affected by the pause in recruitment of new patients.

The trial is evaluating the novel triple combination in two groups of
patients. Firstly, in second line treatment of recurrent or metastatic
HPV-positive cancers including anal, cervical, head and neck, penile, vaginal,
and vulvar cancers in patients who are naïve to checkpoint inhibitors and
have not responded to at least one standard of care therapy. Secondly in third
line treatment of the above recurrent or metastatic HPV-positive cancers in
patients who have not responded to at least two standard of care therapies
including checkpoint inhibitor treatment.

“We are pleased that the NCI, part of the National Institutes of Health,
quickly obtained IRB approval to resume recruitment in this important trial.
We believe the interim data demonstrated that this combination has the
potential to significantly improve clinical outcomes for patients with
advanced, refractory HPV16-positive cancers who have limited treatment
options. Our approach of treating multiple types of cancer based on their
molecular profiles rather than tissue location, may have the potential to
provide safe Versamune®-based treatment options to an expanded population of
patients suffering from multiple types of cancer and at different stages of
disease,” said Dr. Lauren V. Wood, PDS Biotech’s Chief Medical Officer.

For patients interested in enrolling in this clinical study, please call
NCI’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY:
1-800-332-8615), email NCIMO_Referrals@mail.nih.gov, and/or visit the
website: https://trials.cancer.gov.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing
pipeline of cancer immunotherapies based on the Company’s proprietary
Versamune® T-cell activating technology platform. Our Versamune®-based
products have demonstrated the potential to overcome the limitations of
current immunotherapy by inducing in vivo, large quantities of high-quality,
highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer
T-cells. PDS Biotech has developed multiple therapies, based on combinations
of Versamune® and disease-specific antigens, designed to train the immune
system to better recognize diseased cells and effectively attack and destroy
them. The company’s pipeline products address various cancers including
breast, colon, lung, prostate and ovarian cancers. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotech’s lead candidate, PDS0101, combines the utility of the
Versamune® platform with targeted antigens in HPV16-expressing cancers. In
partnership with Merck & Co., PDS Biotech is evaluating a combination of
PDS0101 and KEYTRUDA® in a Phase 2 study (NCT04260126) in first-line
treatment of recurrent or metastatic head and neck cancer, and also in second
line treatment of recurrent or metastatic head and neck cancer in patients who
have failed prior checkpoint inhibitor therapy. PDS Biotech is also conducting
a Phase 2 clinical study in both second- and third-line treatment of multiple
advanced HPV-associated cancers with the National Cancer Institute (NCI). A
third Phase 2 clinical trial in first line treatment of locally advanced
cervical cancer is being performed with The University of Texas, MD Anderson
Cancer Center.

Forward Looking Statements

This communication contains forward-looking statements (including within the
meaning of Section 21E of the United States Securities Exchange Act of 1934,
as amended, and Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the “Company”) and
other matters. These statements may discuss goals, intentions and expectations
as to future plans, trends, events, results of operations or financial
condition, or otherwise, based on current beliefs of the Company’s
management, as well as assumptions made by, and information currently
available to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer to future
events or conditions, and include words such as “may,” “will,”
“should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,”
“forecast,” “guidance”, “outlook” and other similar expressions
among others. Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not guarantees
of future performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various factors,
including, without limitation: the Company’s ability to protect its
intellectual property rights; the Company’s anticipated capital
requirements, including the Company’s anticipated cash runway and the
Company’s current expectations regarding its plans for future equity
financings; the Company’s dependence on additional financing to fund its
operations and complete the development and commercialization of its product
candidates, and the risks that raising such additional capital may restrict
the Company’s operations or require the Company to relinquish rights to the
Company’s technologies or product candidates; the Company’s limited
operating history in the Company’s current line of business, which makes it
difficult to evaluate the Company’s prospects, the Company’s business plan
or the likelihood of the Company’s successful implementation of such
business plan; the timing for the Company or its partners to initiate the
planned clinical trials for PDS0101, PDS0203 and other Versamune® based
products; the future success of such trials; the successful implementation of
the Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101, PDS0203 and other
Versamune® based products and the Company’s interpretation of the results
and findings of such programs and collaborations and whether such results are
sufficient to support the future success of the Company’s product
candidates; the success, timing and cost of the Company’s ongoing clinical
trials and anticipated clinical trials for the Company’s current product
candidates, including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to fully fund
our disclosed clinical trials, which assumes no material changes to our
currently projected expenses), futility analyses, presentations at conferences
and data reported in an abstract, and receipt of interim results, which are
not necessarily indicative of the final results of the Company’s ongoing
clinical trials; any Company statements about its understanding of product
candidates mechanisms of action and interpretation of preclinical and early
clinical results from its clinical development programs and any collaboration
studies; the acceptance by the market of the Company’s product candidates,
if approved; the timing of and the Company’s ability to obtain and maintain
U.S. Food and Drug Administration or other regulatory authority approval of,
or other action with respect to, the Company’s product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company’s control, including unforeseen
circumstances or other disruptions to normal business operations arising from
or related to COVID-19. The foregoing review of important factors that could
cause actual events to differ from expectations should not be construed as
exhaustive and should be read in conjunction with statements that are included
herein and elsewhere, including the risk factors included in the Company’s
annual and periodic reports filed with the SEC. The forward-looking statements
are made only as of the date of this press release and, except as required by
applicable law, the Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking statements,
whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838 
Email: rich@cg.capital

 

(https://www.globenewswire.com/NewsRoom/AttachmentNg/e2e7d124-dbd4-4140-9cc5-449d3488a902)



GlobeNewswire, Inc. 2021
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.